1
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, December 5, 1995: US05472943 (126 worldwide citation)

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side-effects caused by the chronic administratio ...


2
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, August 1, 2000: US06096756 (116 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


3
Stanley M Crain, Ke Fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, April 30, 1996: US05512578 (101 worldwide citation)

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administratio ...


4
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, December 3, 1996: US05580876 (95 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


5
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, June 16, 1998: US05767125 (91 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


6
Stanley M Crain, Ke fei Shen, John A Kessler, Stuart C Apfel: Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, December 17, 1996: US05585348 (83 worldwide citation)

This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nocicep ...


7
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, February 27, 2001: US06194382 (64 worldwide citation)

This invention relates to a method for eating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid recep ...


8
Bo yi Qin, Ke fei Shen, Xiong qi Gong, Stanley M Crain, Mao Huang, Chang Yi Wang: Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction. United Biomedical, Morgan & Finnegan L, April 29, 1997: US05624932 (62 worldwide citation)

The present invention relates to a method of using a bioassay consisting of an electrophysiological method and a cell culture system of dorsal-root ganglion (DRG) neurons to screen and identify opioids with a high potential for use as "low- or non-addictive" analgesics. Another aspect of the inventi ...


9
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, May 28, 2002: US06395705 (61 worldwide citation)

This invention relates to a method for treating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid rec ...


10
Stanley M Crain, Ke Fei Shen, Barry Sherman, Mary Remien, Remi Barbier, Nadav Friedmann: Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects. Pain Therapeutics, Albert Einstein College of Medicine of Yeshiva University, McAndrews Held & Malloy, July 20, 2004: US06765010 (58 worldwide citation)

The invention generally relates to compositions and methods with tramadol and an opioid antagonist to enhance analgesic potency and/or attenuate one or more adverse effects of tramadol, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence) or ...



Click the thumbnails below to visualize the patent trend.